Back

Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Clinical impact of lipid‑lowering strategies Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Chunjian Li

The First Affiliated Hospital of Nanjing Medical University, Nanjing (China)

7 More presentations in this session

Presentation thumbnail
Comparative efficacy of APOC3- and ANGPTL3-targeted therapies in severe hypertriglyceridemia: a systematic review and network meta-analysis
Doctor G. Caldeira Gaelzer (Curitiba, BR)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Quantitative and qualitative lipid responses to lipid-lowering therapy and cardiovascular outcomes after percutaneous coronary intervention for acute myocardial infarction
Doctor K. Lee (Daejeon, KR)
Presentation thumbnail
Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD
Doctor M. Koren (Jacksonville, US)
Abstract Slides
Presentation thumbnail
Treatment with PCSK9 inhibitors reduces the expression of scavenger receptors CD16, CD36 and CD45 in patients with stable coronary artery disease and elevated Lp(a) levels
Doctor S. Ugovsek (Ljubljana, SI)
Abstract Slides

Access the full session

Session thumbnail
Clinical impact of lipid‑lowering strategies

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025
thumbnail
Congress Session
PCSK9 inhibitors for acute coronary syndromes: the era of early implementation
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources